No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes

European Journal of Endocrinology

Volumn 137, Issue 6, 1997, Pages 643-649

  Ahrén, Bo ^a,c   Gutniak, Mark ^b  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; AGED; ARTICLE; BUCCAL DRUG ADMINISTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STIMULATION;

ADULT; AMYLOID; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 0031440316     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1370643     Document Type: Article

References (44)

1. Lukinius A, Wilander E, Westermark GT, Engström U & Westermark P. Colocalization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 1989 32 240-244.
2. Ahrén B & Pettersson M. Calcitonin gene-related peptide (CGRP) and amylin in the endocrine pancreas. International Journal of Pancreatology 1990 6 1-15.
3. Clark A. Islet amyloid: an enigma of type 2 diabetes. Diabetes/Metabolism Reviews 1992 8 117-132.
4. Westermark P, Johnson KH, O'Brien TD & Betsholtz C. Islet amyloid polypeptide - a novel controversy in diabetes research. Diabetologia 1992 35 297-303.
5. Young AA, Gedulin B, Vine W, Percu A & Rink TJ. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 1995 38 642-648.
6. 2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 1996 45 1-3.
7. Butler PC, Chou J, Carter WB, Wang YN, Bu BH, Chang D, Chang JK & Rizza RA. Effect of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 1990 39 752-756.
8. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W & Prager R. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 1991 34 52-54.
9. Ludvik B, Lell B, Hartter E, Schnack C & Prager R. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes 1991 40 1615-1619.
10. Sanke T, Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, Kondo M & Nanjo K. Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991 34 129-132.
11. Ludvik B, Clodi M, Kautzky-Willer A, Chapek M, Hartter E, Pacini G & Prager R. Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Diabetologia 1993 35 84-87.
12. Mitsukawa T, Takemura J, Asai J, Nakazato M, Kangawa K, Matsuo H & Matsukura S. Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration. Diabetes 1990 39 639-642.
13. Eriksson J, Nakazato M, Miyazato M, Shiomi K, Matsukura S & Groop L. Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992 35 291-293.
14. Larsson H & Ahrén B. Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans. Pancreas 1995 11 201-205.
15. Enoki S, Mitsukawa T, Takemura J, Nakazato M, Aburaya J, Toshimori H & Matsukara S. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Research and Clinical Practice 1992 15 97-102.
16. Hanabusa T, Kubo K, Oki C, Nakano Y, Okai K, Sanke T & Nanjo K. Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus. Diabetes Research and Clinical Practice. 1992 15 89-96.
17. Olefsky M, Kolterman OG & Scarlet JA. Insulin action and resistance in obesity and non-insulin dependent type II diabetes mellitus. American Journal of Physiology 1982 243 E15-E30.
18. Mulder H, Ahrén B, Stridsberg M & Sundler F. Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. Diabetologia 1995 38 395-402.
19. Mulder H, Ahrén B & Sundler F. Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats. Diabetologia 1996 39 649-657.
20. Leckström A, Östenson CG, Efendic S, Arnelo U, Permert J, Lundquist I & Westermark P. Increased storage and secretion of islet amyloid polypeptide relative to insulin in the spontaneously diabetic GK rat. Pancreas 1996 13 259-267.
21. van Jaarsveld BC, Hackeng WH, Lips CJ & Erkelens DW. Plasma concentrations of islet amyloid polypeptide after glucagon administration in type 2 diabetic patients and non-diabetic subjects. Diabetic Medicine 1993 10 327-330.
22. Kreymann B, Williams G, Ghatei MA & Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987 2 1300-1303.
23. Fehmann HC, Göke R & Göke B. Glucagon-like peptide-1(7-37)/ (7-36)amide is a new incretin. Molecular and Cellular Endocrinology 1992 85 C39-C44.
24. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R & Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1:7-36 amide but not of synthetic gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of Clinical Investigation 1993 91 301-307.
25. Fehmann HC, Göke R & Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocrine Reviews 1995 16 390-410.
26. Gutniak MA, Ørskov C, Holst JJ, AhreØn B & Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. New England Journal of Medicine 1992 326 1316-1322.
27. Nahan DM, Schreiber E, Mojsov S & Habener JF. Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 1992 15 270-276.
28. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B & Creutzfeldt W. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36)amide in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993 36 741-744.
29. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W & Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. Journal of Clinical Endocrinology and Metabolism 1996 81 327-332.
30. Inoue K, Hisatomi A, Umeda F & Nawata H. Effects of glucagon-like peptide 1 (7-36) amide and glucagon on amylin release from perfused rat pancreas. Hormone and Metabolic Research 1991 23 407-409.
31. Gutniak MA, Larsson H, Heiber SJ, Juneskans OT, Holst JJ & Ahrén B. Potential therapeutic levels of glucagon-like peptide-1 achieved in humans by a buccal tablet. Diabetes Care 1996 19 843-848.
32. Ritzel R, Ørskov C, Holst JJ & Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers: dose-response-relationships. Diabetologia 1995 38 720-725.
33. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhäusl W & Prager R. Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 1994 37 188-194.
34. Kautzky-Willer A, Thomaseth K, Clodi M, Ludvik B, Waldhäusl W, Prager R & Pacini G. β-Cell activity and hepatic insulin extraction following dexamethasone administration in healthy subjects. Metabolism 1996 45 486-491.
35. Kahn SE, Verchere CB, D'Alessio DA, Cook DL & Fujimoto WY. Evidence for selective release of rodent islet amyloid polypeptide through the constitutive secretory pathway. Diabetologia 1993 36 570-573.
36. O'Brien TD, Westermark P & Johnson KH. Islet amyloid polypeptide and insulin secretion from isolated perfused pancreas of fed, fasted, glucose-treated, and dexamethasone-treated rats. Diabetes 1991 40 1701-1706.
37. Pieber TR, Stein DT, Ogawa A, Alam T, Ohneda M, McCorkle K, Chen L, McGarry JD & Unger RH. Amylin-insulin relationships in insulin resistance with and without diabetic hyperglycemia. American Journal of Physiology 1993 265 E446-E453.
38. Novials A, Sarri Y, Casamitjana R, Rivera F & Gomis R. Regulation of islet amyloid polypeptide in human pancreatic islets. Diabetes 1993 42 1514-1519.
39. Mulder H, Ahrén B & Sundler F. Differential expression of islet amyloid polypeptide (amylin) and insulin in experimental diabetes in rodents. Molecular and Cellular Endocrinology 1995 114 101-109.
40. Mulder H, Ahrén B & Sundler F. Islet amyloid polypeptide and insulin gene expression are regulated in parallel by glucose in vivo in rats. American Journal of Physiology 1996 271 E1008-E1014.
41. Hiramatsu S, Inoue K, Sako Y, Umeda F & Nawata H. Insulin treatment improves relative hypersecretion of amylin to insulin in rats with non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin injection. Metabolism 1994 43 776-770.
42. Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky Jr GJ & Porte Jr D. Evidence of cosecretion of islet amyloid polypeptide and insulin by B cells. Diabetes 1990 39 634-638.
43. Bretherton-Watt D, Gilbey SG, Ghatei MA, Beacham J & Bloom SR. Failure to establish islet amyloid polypeptide (amylin) as a circulating beta-cell inhibiting hormone in man. Diabetologia 1990 33 115-117.
44. Sönksen PH, Tompkins CV, Srivastava NC & Nabarro JDN. A comparative study on the metabolism of human insulin and porcine proinsulin in man. Clinical Science of Molecular Medicine 1973 45 633-654